Premium
Altered clozapine bioavailability in patient with feeding tube
Author(s) -
Lam Y. W. Francis
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30677
Subject(s) - clozapine , bioavailability , cyp3a4 , cyp1a2 , pharmacokinetics , cyp2c19 , pharmacology , medicine , schizophrenia (object oriented programming) , cyp2d6 , drug , cytochrome p450 , psychiatry , metabolism
Clozapine is primarily used in patients with treatment‐refractory schizophrenia. Its pharmacokinetic profile reflects variable bioavailability, ranging from 27 to 70%, and complex metabolic pathways, with CYP1A2 as the primary drug‐metabolizing enzyme as well as additional involvement by others (CYP2C19, CYP2D6, and CYP3A4). In addition, enzymatic activity of CYP1A2 is increased by smoking, which is common in patients with schizophrenia.